CDK4 (selective)

Class

small-molecule, primary CDK4-selective inhibitor with approximately 6-fold greater potency for CDK4 over CDK6 and no measurable affinity for CDK9; methylsulfonyl and piperidine-ring structural modifications were designed to reduce CDK6-driven hematologic toxicity and glutathione-capture-mediated liver toxicity risk seen with dual CDK4/6 inhibitors

Pathway

selective CDK4 inhibition blocks Rb phosphorylation and G1-to-S cell-cycle progression while largely sparing CDK6, aiming to reduce the neutropenia associated with non-selective CDK4/6 inhibitors

CDK4 is a cyclin-dependent kinase that, together with its closely related paralog CDK6, controls the transition of cells from the G1 phase of the cell cycle into DNA-synthesis phase (S phase). Partnered with cyclin D, CDK4 phosphorylates the retinoblastoma protein (Rb), releasing transcription factors that activate genes needed for DNA replication. In many cancers, particularly hormone-receptor-driven breast cancer, this pathway is chronically overactive, allowing tumor cells to divide without the normal restraints. Blocking CDK4 activity restores a checkpoint that halts proliferation. Dual inhibitors that block both CDK4 and CDK6 have established this pathway as a validated oncology target, but because CDK6 also supports normal blood cell production in the bone marrow, dual inhibition frequently causes neutropenia (low neutrophil counts). A CDK4-selective inhibitor is designed to preserve the antiproliferative effect on tumor cells, which depend heavily on CDK4, while reducing suppression of CDK6-dependent blood cell formation. This selectivity strategy is relevant broadly wherever cyclin D-CDK4/6-Rb signaling drives tumor growth, with the specific aim of improving the tolerability profile compared with earlier non-selective agents.